RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0045-1812482
Immunotherapy Makes Inroads in Head and Neck Cancer Treatment
Autoren
Abstract
Immunotherapy has transformed the treatment landscape of metastatic head and neck squamous cell carcinoma (HNSCC), but its role in curative-intent settings remained elusive—until now. Recent data from two pivotal phase III trials, NIVOPOSTOP and KEYNOTE-689, mark a turning point by demonstrating statistically significant improvements in disease-free and event-free survival, respectively. However, the magnitude of benefit remains limited, subgroup efficacy is unclear, and overall survival data are immature. Given the logistical complexity and potential for overtreatment, these results warrant cautious interpretation. Future strategies must prioritize biomarker-driven selection, real-world feasibility, and long-term survival outcomes before immunotherapy can claim a definitive role in curative HNSCC.
Patient's Consent
Patient consent is not required.
Publikationsverlauf
Artikel online veröffentlicht:
03. November 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bourhis J, Auperin A, Borel C. et al. NIVOPOSTOP (GORTEC 2018–01): a phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. J Clin Oncol 2025; 43 (17)
- 2 Uppaluri R, Haddad RI, Tao Y. et al; KEYNOTE-689 Investigators. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med 2025; 393 (01) 37-50
- 3 Lee NY, Ferris RL, Psyrri A. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021; 22 (04) 450-462
- 4 Machiels JP, Tao Y, Licitra L. et al; KEYNOTE-412 Investigators. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol 2024; 25 (05) 572-587
- 5 Tao Y, Aupérin A, Sun X. et al. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer 2020; 141: 21-29
- 6 Tao Y, Biau J, Sun XS. et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 2023; 34 (01) 101-110
- 7 Haddad R, Fayette J, Teixeira M. et al. Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial. JAMA 2025; 333 (18) 1599-1607
- 8 Mell LK, Torres-Saavedra PA, Wong SJ. et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol 2024; 25 (12) 1576-1588
- 9 Oliveira G, Egloff AM, Afeyan AB. et al. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol 2023; 8 (87) eadf4968
- 10 Zhao M, Schoenfeld JD, Egloff AM. et al. T cell dynamics with neoadjuvant immunotherapy in head and neck cancer. Nat Rev Clin Oncol 2025; 22 (02) 83-94
- 11 FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma | FDA. Accessed June 18, 2025 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-and-adjuvant-pembrolizumab-resectable-locally-advanced-head-and-neck
- 12 Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study. - ASCO. Accessed June 9, 2025 at: https://www.asco.org/abstracts-presentations/ABSTRACT447778